SAMPLE	CANCER_TYPE	SAMPLE_ALTERATION	ALTERATION_MATCH	TUMOR_MATCH	DRUG	BIOMARKER	EFFECT	BIOMARKER_IDX	RESISTANCE_LIST	RESISTANCE_TYPE	TESTED_TUMOR	EVIDENCE	SOURCE
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR inhibitor 1st gens	EGFR inframe deletion (30-336)	No Responsive	52			G	Early trials	PMID:19204207
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR inhibitor 1st gens	EGFR exon 20 insertions	Resistant	53			L	Late trials	PMID:21764376;PMID:26773740;PMID:26051236
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR inhibitor 1st gens	EGFR amplification	No Responsive	54			G	Early trials	PMID:16282176;PMID:16278407
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR inhibitor 1st gens	EGFR (D761Y)	Resistant	55			NSCLC	Case report	PMID:19680293
default_id	CANCER	EGFR MUT (T790M)	complete	1	EGFR inhibitor 1st gens	EGFR (T790M)	Resistant	56			NSCLC	Late trials	PMID:19680293
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR inhibitor 2nd gens	EGFR inframe deletion (30-336)	No Responsive	57			G	Early trials	PMID:19204207
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR inhibitor 2nd gens	EGFR amplification	No Responsive	59			G	Early trials	PMID:16282176;PMID:16278407
default_id	CANCER	EGFR MUT (T790M)	complete	1	EGFR inhibitor 2nd gens	EGFR (T790M)	Resistant	67			NSCLC	Late trials	PMID:22452896
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR inhibitor 3rd gens	EGFR inframe deletion (30-336)	No Responsive	68			G	Early trials	PMID:19204207
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR inhibitor 3rd gens	EGFR amplification	No Responsive	69			G	Early trials	PMID:16282176;PMID:16278407
default_id	CANCER	AR MUT* (G689*)	only gene	1	AR inhibitor next gens	AR amplification	Responsive	70			PRAD	Pre-clinical	PMID:23589709;PMID:21859989
default_id	CANCER	AR MUT* (G689*)	only gene	1	AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)	AR overexpression	Responsive	71			BRCA	Early trials	ASCO 2015 (abstr 1003)
default_id	CANCER	AR MUT* (G689*)	only gene	1	Enzalutamide (AR inhibitor)	AR overexpression	Responsive	76			PRAD	Early trials	PMID:24882673
default_id	CANCER	AR MUT* (G689*), AR MUT* (G689*)	only alteration type	1	Enzalutamide (AR inhibitor)	AR (F877L) + AR (T878A)	Responsive	78			PRAD	Pre-clinical	PMID:27196756
default_id	CANCER	GLI2 MUT* (R1108C)	only gene	1	SMO inhibitors	GLI2 amplification	Resistant	87			MB	Pre-clinical	PMID:24951114
default_id	CANCER	ATM MUT (E2621D)	complete	1	ATR inhibitors	ATM oncogenic mutation	Responsive	88			COREAD	Case report	ENA 2015 (abstr A48)
default_id	CANCER	ATM MUT (E2621D)	only gene	1	ATR inhibitors	ATM deletion	Responsive	89			COREAD	Case report	ENA 2015 (abstr A48)
default_id	CANCER	ATM MUT (E2621D)	complete	1	DNA-PKc inhibitors	ATM oncogenic mutation	Responsive	90			LY	Pre-clinical	PMID:23761041
default_id	CANCER	ATM MUT (E2621D)	only gene	1	DNA-PKc inhibitors	ATM deletion	Responsive	91			LY	Pre-clinical	PMID:23761041
default_id	CANCER	ATM MUT (E2621D)	complete	1	PARP inhibitors	ATM oncogenic mutation	Responsive	92			ST	Early trials	ENA 2014 (abstr 8LBA)
default_id	CANCER	ATM MUT (E2621D)	only gene	1	PARP inhibitors	ATM deletion	Responsive	93			ST	Early trials	ENA 2014 (abstr 8LBA)
default_id	CANCER	ATM MUT (E2621D)	only alteration type	1	AZD6738 (ATR inhibitor)	ATM biallelic inactivation	Responsive	94			BCL	Early trials	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html
default_id	CANCER	ATM MUT (E2621D)	complete	1	Cisplatin (Chemotherapy)	ATM oncogenic mutation	Responsive	95			BLCA	Early trials	PMID:26238431
default_id	CANCER	ATM MUT (E2621D)	only gene	1	Cisplatin (Chemotherapy)	ATM deletion	Responsive	96			BLCA	Early trials	PMID:26238431
default_id	CANCER	ATM MUT (E2621D)	complete	1	Olaparib (PARP inhibitor)	ATM oncogenic mutation	Responsive	97			ST, PRAD	Early trials	ENA 2014 (abstr 8LBA);PMID:26510020
default_id	CANCER	ATM MUT (E2621D)	complete	1	Temozolomide (Chemotherapy)	ATM oncogenic mutation	Responsive	98			G	Pre-clinical	PMID:23960094
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	PARP inhibitor + Chemotherapys	BRCA2 oncogenic mutation	Responsive	180			OV	Early trials	PMID:22307137;ASCO 2012 (abstr 1009)
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	PD1 Ab inhibitors	BRCA2 oncogenic mutation	Responsive	181			CM	Case report	PMID:26997480
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	PARP inhibitors (Olaparib,etc)	BRCA2 oncogenic mutation	Responsive	182			BRCA	Early trials	PMID:20609467
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	only gene	1	PARP inhibitors (Olaparib,etc)	BRCA2 deletion	Responsive	183			OV	Pre-clinical	PMID:22392482
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Olaparib (PARP inhibitor)	BRCA2 oncogenic mutation	Responsive	184			PRAD	Early trials	PMID:26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Olaparib (PARP inhibitor)	BRCA2 oncogenic mutation	Responsive	185			OV	FDA guidelines	FDA
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Platinum Agent (Chemotherapy)	BRCA2 oncogenic mutation	Responsive	186			BRCA	Early trials	PMID:25847936
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Platinum Agent (Chemotherapy)	BRCA2 oncogenic mutation	Responsive	187			OV	Late trials	PMID:22406760;PMID:22711857
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Platinum Agent (Chemotherapy)	BRCA2 oncogenic mutation	Responsive	188			PA	Case report	PMID:25719666
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Rucaparib (PARP inhibitor)	BRCA2 oncogenic mutation	Responsive	189			OV	FDA guidelines	FDA
default_id	CANCER	BRCA2 MUT* (L1952F), BRCA2 MUT* (F439S)	complete	1	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)	BRCA2 oncogenic mutation	Responsive	190			BRCA	Early trials	PMID:26801247
default_id	CANCER	MET MUT* (W757L)	only gene	1	EGFR inhibitor 1st gens	MET amplification	Resistant	267			NSCLC, COREAD	Early trials	PMID:22189054;PMID:23729478
default_id	CANCER	MET MUT* (W757L)	only gene	1	EGFR mAb inhibitors	MET amplification	Resistant	268			COREAD	Early trials	PMID:23729478
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	MET inhibitors	MET (D1246V)	Resistant	269			LUAD	Case report	PMID:27694386
default_id	CANCER	MET MUT* (W757L), EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR TK inhibitors	MET amplification + EGFR oncogenic mutation	Resistant	270			LUAD	Early trials	ASCO 2015 (abstr 8089)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Retinoic Acids	NF1 oncogenic mutation	Resistant	274			NB	Pre-clinical	PMID:20655465
default_id	CANCER	EGFR MUT (T790M)	complete	1	EGFR inhibitor 3rd gens	EGFR (T790M)	Responsive	275			L	Early trials	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR inhibitors	EGFR amplification	Responsive	276			HNSC	Case report	PMID:26763254
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	EGFR mAb inhibitors	EGFR amplification	Responsive	277			COREAD	Late trials	PMID:18794099;PMID:17664472
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR TK inhibitors	EGFR exon 19 insertions	Responsive	278			L	Late trials	PMID:22753918
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	EGFR TK inhibitors	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Responsive	279			L	Late trials	PMID:22753918
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	HSP90 inhibitors	EGFR exon 19 insertions	Responsive	280			L	Early trials	ESMO 2012 (abstr 4380)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	HSP90 inhibitors	EGFR exon 20 insertions	Responsive	281			L	Case report	ASCO 2014 (abstr 8015)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	HSP90 inhibitors	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Responsive	282			L	Early trials	ESMO 2012 (abstr 4380)
default_id	CANCER	EGFR MUT (T790M)	complete	1	HSP90 inhibitors	EGFR (T790M)	Responsive	283			L	Early trials	ESMO 2012 (abstr 4380)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	MEK inhibitor (alone or in combination)s	EGFR exon 19 insertions	Responsive	284			L	Pre-clinical	PMID:23102728
default_id	CANCER	EGFR MUT (T790M)	complete	1	MEK inhibitor (alone or in combination)s	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	Responsive	285			L	Pre-clinical	PMID:23102728
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	novel EGFR mAb inhibitors	EGFR (S492R)	Responsive	286			COREAD	Early trials	PMID:25962717
default_id	CANCER	EGFR MUT (T790M)	complete	1	EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)	EGFR (T790M)	Responsive	287			NSCLC	Late trials	NCT02322281
default_id	CANCER	EGFR MUT* (L747_E749delLRE)	complete	1	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	EGFR exon 19 deletions	Responsive	288	67	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	EGFR exon 19 insertions	Responsive	289	67	Resistant	L	Late trials	PMID:22753918;PMID:25589191
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	Responsive	290	67	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	Responsive	291	67	Resistant	NSCLC	NCCN guidelines	FDA
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Retinoic Acids	NF1 deletion	Resistant	292			NB	Pre-clinical	PMID:20655465
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	EGFR exon 19 insertions	Responsive	293			L	Early trials	ESMO 2012 (abstr 1289)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	Responsive	294			L	Early trials	ESMO 2012 (abstr 1289)
default_id	CANCER	EGFR MUT (T790M)	complete	1	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	EGFR (T790M)	Responsive	295			L	Early trials	PMID:25074459
default_id	CANCER	EGFR MUT (T790M)	complete	1	Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)	EGFR (T790M)	Responsive	296			L	Early trials	PMID:26667485
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	Cetuximab (EGFR mAb inhibitor)	EGFR overexpression	Responsive	297			COREAD	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Cetuximab (EGFR mAb inhibitor)	EGFR (P546S)	Responsive	298			HNC	Case report	PMID:23578570
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)	EGFR (P753S)	Responsive	299			HNC	Case report	PMID:24934779
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE), EGFR MUT* (intron_variant)	only gene	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR-RAD51 fusion	Responsive	300	56	Resistant	NSCLC	Case report	PMID:27102076
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE), EGFR MUT* (intron_variant)	only gene	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR-RAD51 fusion	Responsive	301	56	Resistant	L	Case report	PMID:27102076
default_id	CANCER	EGFR MUT* (L747_E749delLRE)	complete	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR exon 19 deletions	Responsive	302	56	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR exon 19 insertions	Responsive	303	56	Resistant	L	Early trials	PMID:22190593
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR inframe insertion (769-770)	Responsive	304	56	Resistant	L	Case report	PMID:26773740;PMID:23328547
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (A289V,R108K,G598V,T263P)	Responsive	305	56	Resistant	G	Pre-clinical	PMID:17177598
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (K757R,E746G)	Responsive	307	56	Resistant	L	Case report	PMID:26773740
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (L858R)	Responsive	308	56	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (L858R,L861,G719,S768I)	Responsive	309	56	Resistant	NSCLC	NCCN guidelines	NCCN
default_id	CANCER	EGFR MUT* (L747_E749delLRE)	complete	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR exon 19 deletions	Responsive	312	56	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR amplification	Responsive	315	56	Resistant	ED	Late trials	PMID:24950987
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	Responsive	316	56	Resistant	NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	Responsive	317	56	Resistant	NSCLC	NCCN guidelines	FDA
default_id	CANCER	PIK3CB MUT* (P496Q)	only alteration type	1	PI3K pathway inhibitors	PIK3CB (D1067Y)	Resistant	318			BRCA	Case report	PMID:26759240
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Lapatinib (ERBB2 inhibitor)	EGFR (E690K)	Responsive	319			ED	Case report	PMID:22885469
default_id	CANCER	EGFR MUT* (L747_E749delLRE)	complete	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR exon 19 deletions	Responsive	320			L	Early trials	NCT02465060
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR exon 20 insertions	Responsive	321			L	Pre-clinical	PMID:26515464
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR (L858R)	Responsive	325			L	Early trials	NCT02465060
default_id	CANCER	EGFR MUT (T790M)	complete	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR (T790M)	Responsive	326			NSCLC	FDA guidelines	FDA
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Panitumumab (EGFR mAb inhibitor)	EGFR (S492R)	Responsive	329			COREAD	Case report	PMID:22270724
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Rindopepimut (Vaccine)	EGFR inframe deletion (6-273)	Responsive	330			GB	Late trials	NCT01480479
default_id	CANCER	EPHA2 MUT* (R474S)	only alteration type	1	MTOR inhibitors	EPHA2 (G391R)	Responsive	332			LUSC	Pre-clinical	PMID:20360610
default_id	CANCER	EPHA2 MUT* (R474S)	only alteration type	1	MTOR inhibitors	EPHA2 (G391R)	Responsive	333			LUSC	Pre-clinical	PMID:20360610
default_id	CANCER	EPHA2 MUT* (R474S)	only gene	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	EPHA2 amplification	Responsive	334	614	Resistant	CANCER	Pre-clinical	PMID:18047674;PMID:19010823;PMID:19861960
default_id	CANCER	EPHA2 MUT* (R474S)	only gene	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	EPHA2 amplification	Responsive	335	614	Resistant	CANCER	Pre-clinical	PMID:18047674;PMID:19010823;PMID:19861960
default_id	CANCER	EPHA2 MUT* (R474S)	only alteration type	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	EPHA2 (G391R)	Responsive	336	614	Resistant	LUSC	Pre-clinical	PMID:20360610
default_id	CANCER	EPHA2 MUT* (R474S)	only alteration type	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	EPHA2 (G391R)	Responsive	337	614	Resistant	LUSC	Pre-clinical	PMID:20360610
default_id	CANCER	EPHA3 MUT* (R799S)	only gene	1	EPHA3 inhibitors	EPHA3 amplification	Responsive	338			CANCER	Pre-clinical	PMID:25125683
default_id	CANCER	EPHA3 MUT* (R799S)	only gene	1	EPHA3 inhibitors	EPHA3 amplification	Responsive	339			CANCER	Pre-clinical	PMID:25125683
default_id	CANCER	ERBB4 MUT* (R47R)	only gene	1	Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)	ERBB4 fusion	Responsive	411			LUAD	Pre-clinical	PMID:24727320
default_id	CANCER	EZH2 MUT* (M743I)	only alteration type	1	EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)	EZH2 (Y641,A677)	Responsive	427			LY	Pre-clinical	PMID:23023262;PMID:24563539
default_id	CANCER	FANCA MUT* (R600S)	complete	1	Olaparib (PARP inhibitor)	FANCA oncogenic mutation	Responsive	428			PRAD	Case report	PMID:26510020
default_id	CANCER	FANCA MUT* (R600S)	only gene	1	Olaparib (PARP inhibitor)	FANCA deletion	Responsive	429			PRAD	Case report	PMID:26510020
default_id	CANCER	FAT1 MUT (S1912*)	complete	1	BET inhibitors	FAT1 oncogenic mutation	Responsive	432			HNSC	Pre-clinical	PMID:27397505
default_id	CANCER	AR MUT* (G689*)	only gene	1	Abiraterone (AR inhibitor)	AR amplification	Resistant	445			PRAD	Early trials	PMID:26537258
default_id	CANCER	AR MUT* (G689*)	only alteration type	1	Abiraterone (AR inhibitor)	AR (L702H,T878A)	Resistant	446			PRAD	Early trials	PMID:26537258
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	Panitumumab (EGFR mAb inhibitor)	EGFR overexpression	Resistant	451			COREAD	FDA guidelines	FDA guidelines
default_id	CANCER	FGFR3 MUT* (S221S)	only gene	1	FGFR inhibitors	FGFR3 fusion	Responsive	458			G	Early trials	PMID:26324363
default_id	CANCER	AR MUT* (G689*)	only alteration type	1	Arn-509 (AR inhibitor)	AR (F877L)	Resistant	462			PRAD	Case report	PMID:23779130
default_id	CANCER	FGFR3 MUT* (S221S)	only gene	1	FGFR inhibitors	FGFR3 fusion	Responsive	463			BLCA	Case report	PMID:26324363;ASCO 2017 (abstr 2500)
default_id	CANCER	FGFR3 MUT* (S221S)	only gene	1	FGFR inhibitors (,etc)	FGFR3-TACC3 fusion	Responsive	465			NSCLC	Pre-clinical	PMID:25294908
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Cediranib (ALK inhibitor)	NF1 oncogenic mutation	No Responsive	483			PLEN	Early trials	NCT00326872
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Cediranib (ALK inhibitor)	NF1 deletion	No Responsive	484			PLEN	Early trials	NCT00326872
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Cetuximab (EGFR mAb inhibitor)	EGFR (S464L,G465R,I491M)	Resistant	521			COREAD	Pre-clinical	PMID:25623215
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Cetuximab (EGFR mAb inhibitor)	EGFR (S492R,G465R,R451C,K467T)	Resistant	522			COREAD	Case report	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827
default_id	CANCER	JAK2 MUT* (R867R)	only gene	1	Ruxolitinib (JAK inhibitor)	JAK2-BRAF fusion	Responsive	535			ALL	Pre-clinical	PMID:22875628;PMID:22899477
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	Crizotinib (ALK inhibitor)	MET (Y1230C;Y1235D)	Resistant	592			CANCER	Pre-clinical	PMID:17483355
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	NF1 oncogenic mutation	Resistant	614			L	Pre-clinical	PMID:24296828
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Dasatinib (BCR-ABL inhibitor 2nd gen)	NF1 deletion	Resistant	616			L	Pre-clinical	PMID:24296828
default_id	CANCER	AR MUT* (G689*)	only alteration type	1	Enzalutamide (AR inhibitor)	AR (F877L)	Resistant	620			PRAD	Case report	PMID:23779130
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR amplification	No Responsive	624			L	Early trials	ASCO2015(abstre19028)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (S720)	No Responsive	625			L	Case report	PMID:26773740
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Erlotinib (EGFR inhibitor 1st gen)	NF1 oncogenic mutation	Resistant	628			L	Pre-clinical	PMID:24535670
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Erlotinib (EGFR inhibitor 1st gen)	NF1 deletion	Resistant	629			L	Pre-clinical	PMID:24535670
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus (MTOR inhibitor)	NF1 oncogenic mutation	No Responsive	637			MPN	Early trials	NCT01365468
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Everolimus (MTOR inhibitor)	NF1 deletion	No Responsive	638			MPN	Early trials	NCT01365468
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)	NF1 oncogenic mutation	No Responsive	639			MPN	Early trials	ASCO 2016 (abstr 11053)
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)	NF1 deletion	No Responsive	644			MPN	Early trials	ASCO 2016 (abstr 11053)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)	NF1 oncogenic mutation	No Responsive	646			G	Case report	PMID:24634382
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)	NF1 deletion	No Responsive	647			G	Case report	PMID:24634382
default_id	CANCER	AR MUT* (G689*)	only alteration type	1	Flutamide (AR inhibitor)	AR (T878A)	Resistant	649			PRAD	Case report	PMID:2260966
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR inframe deletion (L747),inframe insertion (P753PS)	No Responsive	652			HNC	Case report	PMID:21274259
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only gene	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR amplification	No Responsive	654			HNC	Early trials	PMID:21274259;PMID:22261807
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	Savolitinib (MET inhibitor)	MET kinase domain mutation	Responsive	655			R	Early trials	PMID:28644771
default_id	CANCER	MET MUT* (W757L)	only gene	1	BCL2 inhibitors	MET amplification	Responsive	656			COREAD	Pre-clinical	PMID:27397505
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Gefitinib (EGFR inhibitor 1st gen)	EGFR (V843I)	No Responsive	657			HNC	Case report	PMID:21274259
default_id	CANCER	MET MUT* (W757L)	only gene	1	MET inhibitors	MET amplification	Responsive	659			HC	Case report	ENA 2015 (abstract A55)
default_id	CANCER	MET MUT* (W757L)	only gene	1	MET inhibitors	MET amplification	Responsive	660			ST	Pre-clinical	PMID:22729845;PMID:23327903
default_id	CANCER	MET MUT* (W757L)	only gene	1	MET inhibitors	MET amplification	Responsive	661			R	Early trials	PMID:23213094;AACR 2016 (abstr CT2006)
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	MET inhibitors	MET (H1112R)	Responsive	663			R	Early trials	PMID:23213094
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	MET inhibitors	MET (M1268T)	Responsive	664			R	Case report	PMID:23610116
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	MET inhibitors (Crizotinib,etc)	MET (H1112L)	Responsive	665			CANCER	Pre-clinical	AACR 2012 (abstr 1786)
default_id	CANCER	MET MUT* (W757L)	only gene	1	Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)	MET amplification	Responsive	666			COREAD	Case report	ENA 2015 (abstr A52)
default_id	CANCER	MET MUT* (R1022R), MET MUT* (W757L)	only gene	1	Crizotinib (ALK inhibitor)	MET fusion	Responsive	667			G	Case report	PMID:27748748
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	Crizotinib (ALK inhibitor)	MET mutation in exon 16-19	Responsive	668			R	Early trials	AACR 2016 (abstr CT2006)
default_id	CANCER	MET MUT* (W757L)	only gene	1	Crizotinib (ALK inhibitor)	MET amplification	Responsive	669			NSCLC	Early trials	NCT02499614;ASCO 2015 (abstr 2595)
default_id	CANCER	MET MUT* (W757L)	only gene	1	Crizotinib (ALK inhibitor)	MET amplification	Responsive	670			LUAD, ST	Early trials	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)
default_id	CANCER	MET MUT* (W757L)	only gene	1	Crizotinib (ALK inhibitor)	MET amplification	Responsive	671			G	Case report	PMID:22162573
default_id	CANCER	MET MUT* (W757L)	only alteration type	1	Crizotinib (ALK inhibitor)	MET (V1110I,H1112R,M1268T,R988C,T1010I)	Responsive	672			CANCER	Pre-clinical	PMID:17483355
default_id	CANCER	MLL MUT* (I299F)	only gene	1	BET inhibitors	MLL fusion	Responsive	687			AML	Pre-clinical	PMID:21964340
default_id	CANCER	MLL MUT* (I299F)	only gene	1	Belinostat (HDAC inhibitor)	MLL fusion	Responsive	688			AML	Early trials	NCT00351975;NCT00357032;PMID:22015773
default_id	CANCER	MLL MUT* (I299F)	only gene	1	Daunorubicin (Chemotherapy)	MLL fusion	Responsive	689			AML	FDA guidelines	PMID:22417203
default_id	CANCER	MLL MUT* (I299F)	only gene	1	EPZ-5676 (DOTL1 inhibitor)	MLL fusion	Responsive	690			AML, ALL, MDS	Early trials	NCT02141828;NCT01684150;PMID:21741596
default_id	CANCER	MLL2 MUT* (R3536S)	complete	1	Bicalutamide (AR inhibitor)	MLL2 oncogenic mutation	Responsive	691			LUSC	Pre-clinical	PMID:27397505
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	AURK inhibitors	NF1 oncogenic mutation	Responsive	709			MPN	Pre-clinical	PMID:24373973
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	AURK inhibitors	NF1 deletion	Responsive	710			MPN	Pre-clinical	PMID:24373973
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	BRD4 inhibitors	NF1 oncogenic mutation	Responsive	711			MPN	Pre-clinical	PMID:24373973
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	BRD4 inhibitors	NF1 deletion	Responsive	712			MPN	Pre-clinical	PMID:24373973
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	KIT inhibitor + MTOR inhibitors	NF1 oncogenic mutation	Responsive	713			MPN	Pre-clinical	PMID:24718867
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	KIT inhibitor + MTOR inhibitors	NF1 deletion	Responsive	714			MPN	Pre-clinical	PMID:24718867
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	MEK inhibitors	NF1 oncogenic mutation	Responsive	715			MPN	Pre-clinical	PMID:23221341
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	MEK inhibitors	NF1 oncogenic mutation	Responsive	716			G, LK	Pre-clinical	PMID:22573716;PMID:19727076
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	MEK inhibitors	NF1 deletion	Responsive	717			MPN	Pre-clinical	PMID:23221341
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	MEK inhibitors	NF1 deletion	Responsive	718			G, LK	Pre-clinical	PMID:22573716;PMID:19727076
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	MTOR inhibitor + HSP90 inhibitors	NF1 oncogenic mutation	Responsive	719			MPN	Pre-clinical	PMID:21907929
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	MTOR inhibitor + HSP90 inhibitors	NF1 deletion	Responsive	720			MPN	Pre-clinical	PMID:21907929
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	MTOR inhibitors	NF1 oncogenic mutation	Responsive	721			G, MPN, LK	Pre-clinical	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	MTOR inhibitors	NF1 deletion	Responsive	722			G, MPN, LK	Pre-clinical	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Pan-RAF inhibitor + MEK inhibitors	NF1 oncogenic mutation	Responsive	723			CM	Pre-clinical	PMID:26351322
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Pan-RAF inhibitor + MEK inhibitors	NF1 deletion	Responsive	724			CM	Pre-clinical	PMID:26351322
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	PD1 Ab inhibitors	NF1 oncogenic mutation	Responsive	725			CM	Early trials	ASCO 2016 (abstr 105)
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	PD1 Ab inhibitors	NF1 deletion	Responsive	726			CM	Early trials	ASCO 2016 (abstr 105)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Bevacizumab (VEGFR mAb inhibitor)	NF1 oncogenic mutation	Responsive	729			G	Case report	PMID:24232489;PMID:2485933
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Bevacizumab (VEGFR mAb inhibitor)	NF1 deletion	Responsive	730			G	Case report	PMID:24232489;PMID:2485933
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus (MTOR inhibitor)	NF1 oncogenic mutation	Responsive	738			HNC, SG	Case report	PMID:26859683;ASCO 2016 (abstr e17557)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus (MTOR inhibitor)	NF1 oncogenic mutation	Responsive	739			NF	Late trials	NCT01365468
default_id	CANCER	NF1 MUT* (L1201F)	only alteration type	1	Everolimus (MTOR inhibitor)	NF1 (D1644A)	Responsive	740			HNC	Case report	ASCO 2015 (abstr 11010);PMID:26859683
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Everolimus (MTOR inhibitor)	NF1 deletion	Responsive	742			HNC, SG	Case report	PMID:26859683;ASCO 2016 (abstr e17557)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)	NF1 oncogenic mutation	Responsive	747			HC	Case report	PMID:24931142
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	NF1 oncogenic mutation	Responsive	748			PLEN	Early trials	PMID:23099009
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	NF1 deletion	Responsive	749			PLEN	Early trials	PMID:23099009
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Nilotinib (BCR-ABL inhibitor 2nd gen)	NF1 oncogenic mutation	Responsive	750			PLEN, MPN	Pre-clinical	PMID:24173684
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Nilotinib (BCR-ABL inhibitor 2nd gen)	NF1 deletion	Responsive	751			PLEN, MPN	Pre-clinical	PMID:24173684
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	PLX3397 (Pan-TK inhibitor)	NF1 oncogenic mutation	Responsive	752			PLEN	Pre-clinical	PMID:23099891
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	PLX3397 (Pan-TK inhibitor)	NF1 deletion	Responsive	753			PLEN	Pre-clinical	PMID:23099891
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Selumetinib (MEK inhibitor)	NF1 oncogenic mutation	Responsive	754			PLEN	Early trials	ASCO 2014 (abstr 10018)
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Selumetinib (MEK inhibitor)	NF1 deletion	Responsive	755			PLEN	Early trials	ASCO 2014 (abstr 10018)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Sirolimus (MTOR inhibitor)	NF1 oncogenic mutation	Responsive	756			PLEN	Early trials	PMID:25314964
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Sirolimus (MTOR inhibitor)	NF1 deletion	Responsive	757			PLEN	Early trials	PMID:25314964
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)	NF1 oncogenic mutation	Responsive	758			G	Case report	PMID:22434731
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)	NF1 deletion	Responsive	759			G	Case report	PMID:22434731
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)	NF1 oncogenic mutation	Responsive	760			MPN	Pre-clinical	PMID:25810463
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)	NF1 deletion	Responsive	761			MPN	Pre-clinical	PMID:25810463
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Tamoxifen (Hormonal therapy)	NF1 oncogenic mutation	Responsive	762			MPN	Pre-clinical	PMID:21075781
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Tamoxifen (Hormonal therapy)	NF1 deletion	Responsive	763			MPN	Pre-clinical	PMID:21075781
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Trametinib (MEK inhibitor)	NF1 oncogenic mutation	Responsive	766			G	Case report	PMID:26936308
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Trametinib (MEK inhibitor)	NF1 oncogenic mutation	Responsive	767			CM	Pre-clinical	PMID:24576830;PMID:2524381
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Trametinib (MEK inhibitor)	NF1 deletion	Responsive	768			G	Case report	PMID:26936308
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Trametinib (MEK inhibitor)	NF1 deletion	Responsive	769			CM	Pre-clinical	PMID:24576830;PMID:2524381
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR (C797S)	Resistant	770			L	Early trials	PMID:25939061
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR (L718)	Resistant	771			L	Early trials	ASCO 2017 (abstr 2572)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Vinblastine (Chemotherapy)	NF1 oncogenic mutation	Responsive	772			G	Early trials	ASCO 2016 (abstr 2019)
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Vinblastine (Chemotherapy)	NF1 deletion	Responsive	773			G	Early trials	ASCO 2016 (abstr 2019)
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)	NF1 oncogenic mutation	Responsive	774			G	Case report	ASCO 2016 (abstr 10555)
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)	NF1 deletion	Responsive	775			G	Case report	ASCO 2016 (abstr 10555)
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Osimertinib (EGFR inhibitor 3rd gen)	EGFR (L792)	Resistant	776			L	Early trials	ASCO 2017 (abstr 2572)
default_id	CANCER	MET MUT* (W757L)	only gene	1	EGFR inhibitor 3rd gens (Osimertinib,etc)	MET amplification	Resistant	778			LUAD	Case report	PMID:27252416
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Panitumumab (EGFR mAb inhibitor)	EGFR (G465R)	Resistant	803			COREAD	Case report	PMID:26059438
default_id	CANCER	EGFR MUT (T790M)	complete	1	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	EGFR (T790M)	Resistant	832			L	NCCN/CAP guidelines	NCCN
default_id	CANCER	NTRK3 MUT* (intron_variant), NTRK3 MUT* (R678R)	only gene	1	IGF1R inhibitors	NTRK3 fusion	Responsive	853			BRCA	Pre-clinical	PMID:21148487;PMID:23131561
default_id	CANCER	NTRK3 MUT* (intron_variant), NTRK3 MUT* (R678R)	only gene	1	PI3K pathway inhibitors	NTRK3 fusion	Responsive	854			BRCA	Pre-clinical	PMID:21148487;PMID:23131561
default_id	CANCER	NTRK3 MUT* (intron_variant), NTRK3 MUT* (R678R)	only gene	1	Midostaurin (Pan-TK inhibitor)	NTRK3 fusion	Responsive	855			BRCA	Pre-clinical	PMID:21148487;PMID:23131561
default_id	CANCER	EGFR MUT (T790M)	complete	1	Erlotinib (EGFR inhibitor 1st gen)	EGFR (T790M)	Resistant	881			L	NCCN/CAP guidelines	NCCN
default_id	CANCER	EGFR MUT (T790M), EGFR MUT (P848Q), EGFR MUT* (L747_E749delLRE)	only alteration type	1	Rociletinib (EGFR inhibitor)	EGFR (L798I)	Resistant	886			LUAD	Case report	PMID:27283993
default_id	CANCER	MET MUT* (W757L)	only gene	1	EGFR inhibitor 3rd gens (Rociletinib,etc)	MET amplification	Resistant	897			LUAD	Case report	PMID:27252416
default_id	CANCER	PIK3CB MUT* (P496Q)	complete	1	AKT inhibitors	PIK3CB oncogenic mutation	Responsive	903			HNSC	Pre-clinical	PMID:23619167
default_id	CANCER	PIK3CB MUT* (P496Q)	only alteration type	1	AKT inhibitors	PIK3CB (D1067Y)	Responsive	904			BRCA	Pre-clinical	PMID:26759240
default_id	CANCER	PIK3CB MUT* (P496Q)	complete	1	MTORC1/2 inhibitors	PIK3CB oncogenic mutation	Responsive	905			HNSC	Pre-clinical	PMID:23619167
default_id	CANCER	PIK3CB MUT* (P496Q)	only alteration type	1	MTORC1/2 inhibitors	PIK3CB (D1067Y)	Responsive	906			BRCA	Pre-clinical	PMID:26759240
default_id	CANCER	PIK3CB MUT* (P496Q)	complete	1	PI3K pathway inhibitors	PIK3CB oncogenic mutation	Responsive	907			HNSC	Pre-clinical	PMID:23619167
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Tipifarnib (Farnesyltransferase inhibitor)	NF1 oncogenic mutation	No Responsive	945			PLEN	Early trials	PMID:24500418
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Tipifarnib (Farnesyltransferase inhibitor)	NF1 deletion	No Responsive	948			PLEN	Early trials	PMID:24500418
default_id	CANCER	NF1 MUT* (L1201F)	complete	1	Trametinib (MEK inhibitor)	NF1 oncogenic mutation	No Responsive	949			OS	Case report	PMID:26325560
default_id	CANCER	RAD50 MUT (E639*), ATM MUT (E2621D)	only gene	1	Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)	RAD50 (L1237F) + ATM deletion	Responsive	950			CANCER	Case report	PMID:24934408
default_id	CANCER	NF1 MUT* (L1201F)	only gene	1	Trametinib (MEK inhibitor)	NF1 deletion	No Responsive	957			OS	Case report	PMID:26325560
default_id	CANCER	ROS1 MUT* (intron_variant)	only gene	1	HSP90 inhibitors	ROS1 fusion	Responsive	981			LUAD	Pre-clinical	PMID:23533265
default_id	CANCER	ROS1 MUT* (intron_variant)	only gene	1	Cabozantinib (Pan-kinase inhibitor)	ROS1 fusion	Responsive	982			LUAD	Case report	PMID:27370605
default_id	CANCER	ROS1 MUT* (intron_variant)	only gene	1	Crizotinib (ALK inhibitor)	ROS1 fusion	Responsive	985			IM	Case report	PMID:24875859
default_id	CANCER	ROS1 MUT* (intron_variant)	only gene	1	Crizotinib (ALK inhibitor)	ROS1 fusion	Responsive	986			LUAD	Early trials	PMID:25264305
default_id	CANCER	ROS1 MUT* (intron_variant)	only gene	1	Crizotinib (ALK inhibitor)	ROS1 fusion	Responsive	987			NSCLC	FDA guidelines	FDA
default_id	CANCER	SF3B1 MUT (L743F)	only alteration type	1	Spliceosome inhibitors	SF3B1 (K700E,K666N)	Responsive	994			CANCER	Pre-clinical	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858
default_id	CANCER	NF1 MUT* (L1201F)	only alteration type	1	Vemurafenib (BRAF inhibitor)	NF1 biallelic inactivation	Resistant	1023			CM	Pre-clinical	PMID:23171796
